What's in IBSA Institut Biochimique SA's pipeline?

IBSA Institut Biochimique SA has 11 drugs in our index: 4 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with IBSA Institut Biochimique SA's portfolio?

Top competitors by shared drug class: Pfizer, Bayer, Sanofi, Insel Gruppe AG, University Hospital Bern, Organon and Co.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ibsa-institut-biochimique-sa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

IBSA Institut Biochimique SA — Portfolio Competitive Intelligence Brief

IBSA Institut Biochimique SA pipeline: 4 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 7 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Proton pump inhibitor (PPI)	Proton pump inhibitor (PPI)	marketed	Proton pump inhibitor	H+/K+-ATPase (proton pump)	Gastroenterology
Urofollitrophin	Urofollitrophin	marketed			Other
Diclofenac hydroxyethylpyrrolidine	Diclofenac hydroxyethylpyrrolidine	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)	Pain management, Rheumatology, Inflammation
Tirosint®-SOL	Tirosint®-SOL	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha and TR-beta)	Endocrinology
Diclofenac HPBCD	Diclofenac HPBCD	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2	Pain management, Rheumatology, Inflammation
Placebo injectable solution	Placebo injectable solution	phase 3
FSH-IBSA	FSH-IBSA	phase 3	Gonadotropin	FSH receptor (FSHR)	Reproductive Medicine / Fertility
Progesterone-IBSA Injectable Solution	Progesterone-IBSA Injectable Solution	phase 3	Progestin	Progesterone receptor (PR)	Obstetrics/Gynecology
Progesterone Vaginal Gel with Applicator	Progesterone Vaginal Gel with Applicator	phase 3	Progestogen		Women's Health
hCG-IBSA	hCG-IBSA	phase 3
hMG-IBSA	hMG-IBSA	phase 3	gonadotropin	FSH receptor	Reproductive Health

Therapeutic area mix

Pain management, Rheumatology, Inflammation · 2
Gastroenterology · 1
Obstetrics/Gynecology · 1
Other · 1
Reproductive Health · 1
Reproductive Medicine / Fertility · 1
Endocrinology · 1
Women's Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 3 shared drug classes
Bayer · 3 shared drug classes
Sanofi · 2 shared drug classes
Insel Gruppe AG, University Hospital Bern · 2 shared drug classes
Organon and Co · 2 shared drug classes
Bezmialem Vakif University · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Takeda · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for IBSA Institut Biochimique SA:

Cite this brief

Drug Landscape (2026). IBSA Institut Biochimique SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ibsa-institut-biochimique-sa. Accessed 2026-05-16.